Specific targeting of BCL-2 by siRNA in various malignancies including breast cancer demonstrated growth inhibition, apoptosis induction, and enhanced susceptibility to chemotherapy in vitro and preliminary in vivo studies [12,52,53,54,55,56,57,58]. This evidence concerns the gene BCL2 and breast carcinoma.